专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US12030879B2 Sulfonyl acetamides as NLRP3 inhibitors 有权
公开(公告)号：US12030879B2
公开(公告)日：2024-07-09
申请号：US16977445
申请日：2019-03-01
申请人： Inflazome Limited
发明人： Matthew Cooper , David Miller , Jimmy Van Wiltenburg , Johannes Wilhem Georg Meissner , Jochem Theodoor Van Herpt , Zhou Min Lion , Jonathan Shannon , Stephen St-Gallay
IPC分类号： C07D471/04 , A61K9/00 , C07D213/64 , C07D213/643 , C07D213/71 , C07D401/04 , C07D401/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07F5/02
CPC分类号： C07D471/04 , A61K9/0014 , C07D213/64 , C07D213/643 , C07D213/71 , C07D401/04 , C07D401/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07F5/027
摘要： The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted hydrocarbyl group optionally including one or more heteroatoms N, O or S; R2 is a cyclic group substituted at the a and a′ positions, wherein the substituent at the α-position is a monovalent heterocyclic group or a monovalent aromatic group, wherein the heterocyclic or aromatic group may optionally be substituted, and wherein the cyclic group may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated, optionally substituted cyclic group; and R5 is independently optionally substituted C1-C4 alkyl. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

2. 发明授权

US11884645B2 Sulfonyl acetamides as NLRP3 inhibitors 有权
公开(公告)号：US11884645B2
公开(公告)日：2024-01-30
申请号：US16977452
申请日：2019-03-01
申请人： Inflazome Limited
发明人： David Miller , Jimmy Van Wiltenburg , Matthew Cooper
IPC分类号： C07D401/12 , C07D231/18
CPC分类号： C07D401/12 , C07D231/18
摘要： The present invention relates to compounds of formula (1): wherein Q is selected from O or S; R1 is a 5-membered nitrogen-containing heteroaryl group substituted with R6 and optionally further substituted; R2 is an alpha, alpha′-substituted cyclic group which may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3 to 7 membered saturated or unsaturated, optionally substituted cyclic group; R5 is independently an optionally substituted C1-C4 alkyl group; and R6 is any group comprising a nitrogen atom. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

3. 发明授权

US11530200B2 Compounds 有权
公开(公告)号：US11530200B2
公开(公告)日：2022-12-20
申请号：US16977451
申请日：2019-03-01
申请人： Inflazome Limited
发明人： Matthew Cooper , David Miller , Jimmy Van Wiltenburg
IPC分类号： C07D405/04 , C07D231/20 , C07D233/84 , C07D249/04 , C07D401/12 , C07D405/14
摘要： The present invention relates to compounds of formula (I), wherein Q is selected from O or S; R1 is a 5- or 6-membered heteroaryl group consisting of one or more carbon atoms, and one or more nitrogen and/or oxygen atoms, and substituted with a monovalent, optionally substituted cycloalkyl, cycloalkenyl or heterocyclic group, wherein the 5- or 6-membered heteroaryl group of R1 may optionally be further substituted; R2 is an α,α′-substituted cyclic group which may optionally be further substituted; R3 and R4 are each independently hydrogen, halogen, —OH, —NH2, —CN, —R5, —OR5, —NHR5 or —N(R5)2; or R3 and R4 together with the carbon atom to which they are attached may form a 3- to 7-membered saturated or unsaturated, optionally substituted cyclic group; and R5 is independently an optionally substituted C1-C4 alkyl group. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

4. 发明授权

US11518739B2 Sulfonamide carboxamide compounds 有权
公开(公告)号：US11518739B2
公开(公告)日：2022-12-06
申请号：US16638708
申请日：2018-08-15
申请人： Inflazome Limited
发明人： David Miller , Angus Macleod , Jimmy Van Wiltenburg , Stephen Thom , Stephen St-Gallay , Jonathan Shannon
IPC分类号： C07C311/55 , C07D213/40 , C07D213/64 , C07D213/84
摘要： The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated, optionally substituted C1-C15 hydrocarbyl group, wherein the atom of R1 which is attached to the sulfur atom of the sulfonylurea group is not a ring atom of a cyclic group; and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

5. 发明授权

US11773058B2 Sulfonamide carboxamide compounds 有权
公开(公告)号：US11773058B2
公开(公告)日：2023-10-03
申请号：US16638646
申请日：2018-08-15
申请人： Inflazome Limited
发明人： David Miller , Angus MacLeod , Jimmy Van Wiltenburg , Stephen Thom , Stephen St-Gallay , Jonathan Shannon
IPC分类号： C07C311/55 , C07D205/04 , C07D205/12 , C07D207/09 , C07D211/24 , C07D211/58 , C07D213/34 , C07D213/40 , C07D231/12 , C07D295/088
CPC分类号： C07C311/55 , C07D205/04 , C07D205/12 , C07D207/09 , C07D211/24 , C07D211/58 , C07D213/34 , C07D213/40 , C07D231/12 , C07D295/088
摘要： The present invention relates to compounds of formula (I): Formula (I) wherein Q is selected from O or S; L is a saturated or unsaturated, optionally substituted C1-C12 hydrocarbylene group optionally including one or more heteroatoms N, O or S; R1 is —NR3R4, —OR5, —(C═NR6)R7, —(CO)R8, —CN, —N3, a quaternary ammonium group or an optionally substituted heterocycle; R3, R4, R5, R6, R7 and R8 are each independently hydrogen or a saturated or unsaturated, optionally substituted C1-C10 hydrocarbyl group optionally including one or more heteroatoms N, O or S; wherein optionally L and R3, or L and R4, or R3 and R4, or L and R5, or L and R6, or L and R7, or R6 and R7, or L and R8 together with the atom(s) to which they are attached may form a 3- to 12-membered, saturated or unsaturated, optionally substituted cyclic group; and R2 is a cyclic group substituted at the a-position, wherein R2 may optionally be further substituted; provided that the atom of L which is attached to the sulfur atom of the sulfonylurea group is a carbon atom and is not a ring atom of a heterocyclic or aromatic group. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

6. 发明授权

US11370776B2 Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors 有权
公开(公告)号：US11370776B2
公开(公告)日：2022-06-28
申请号：US16629027
申请日：2018-07-04
申请人： Inflazome Limited
发明人： Matthew Cooper , David Miller , Angus Macleod , Jimmy Van Wiltenburg , Stephen Thom , Stephen St-Gallay , Jonathan Shannon
IPC分类号： C07D401/12 , C07D213/71 , C07D237/18 , C07D239/38 , C07D239/47 , C07D241/18 , C07D241/20 , C07D241/44 , C07D403/04 , C07D413/04 , C07D471/04 , G01N33/50
摘要： The present invention relates to compounds of formula (I): wherein Q is O or S, R1 is a 6-membered heteroaryl group containing at least one nitrogen atom in the 6-membered ring structure, wherein R1 may optionally be substituted, and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

7. 发明授权

US11981667B2 Sulfonamide carboxamide compounds 有权
公开(公告)号：US11981667B2
公开(公告)日：2024-05-14
申请号：US17889300
申请日：2022-08-16
申请人： INFLAZOME LIMITED
发明人： Matthew Cooper , David Miller , Angus MacLeod , Jimmy Van Wiltenburg , Stephen Thom , Stephen St-Gallay , Jonathan Shannon
IPC分类号： C07D409/04 , C07D205/04 , C07D205/12 , C07D207/12 , C07D211/54 , C07D211/96 , C07D215/36 , C07D223/06 , C07D239/60 , C07D241/18 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/06 , C07D453/02 , C07D471/08
CPC分类号： C07D409/04 , C07D205/04 , C07D205/12 , C07D207/12 , C07D211/54 , C07D211/96 , C07D215/36 , C07D223/06 , C07D239/60 , C07D241/18 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/06 , C07D453/02 , C07D471/08
摘要： The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R1 may optionally be substituted; and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

8. 发明授权

US11834433B2 Compounds 有权
公开(公告)号：US11834433B2
公开(公告)日：2023-12-05
申请号：US16977251
申请日：2019-03-01
申请人： INFLAZOME LIMITED
发明人： David Miller , Jimmy Van Wiltenburg , Matthew Cooper
IPC分类号： C07D401/12 , C07D231/18 , C07D405/04 , C07D405/14
CPC分类号： C07D401/12 , C07D231/18 , C07D405/04 , C07D405/14
摘要： The present invention relates to compounds of formula (I): comprising a 5-membered nitrogen-containing heteroaryl ring A, wherein the heteroaryl ring A is substituted with at least one group containing an oxygen atom, and wherein said oxygen atom is attached to the heteroaryl ring A via at least two other atoms. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

9. 发明授权

US11465992B2 Sulfonamide carboxamide compounds 有权
公开(公告)号：US11465992B2
公开(公告)日：2022-10-11
申请号：US16629006
申请日：2018-07-04
申请人： Inflazome Limited
发明人： Matthew Cooper , David Miller , Angus MacLeod , Jimmy Van Wiltenburg , Stephen Thom , Stephen St-Gallay , Jonathan Shannon
IPC分类号： C07D409/04 , C07D205/04 , C07D205/12 , C07D207/12 , C07D211/54 , C07D211/96 , C07D215/36 , C07D223/06 , C07D239/60 , C07D241/18 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/06 , C07D453/02 , C07D471/08
摘要： The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R1 may optionally be substituted; and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式